News
8/5/2020

New study to assess the efficacy of hydroxychloroquine in the prevention and treatment of COVID-19 in pregnant women

New study to assess the efficacy of hydroxychloroquine in the prevention and treatment of COVID-19 in pregnant women


News from ISGlobal


Hospitals in Barcelona and Madrid, the two Spanish cities hit hardest by the COVID-19 epidemic to date, will participate in COVID-Preg, a clinical trial coordinated by the Barcelona Institute for Global Health (ISGlobal) and Hospital Clínic. The objective of this new study is to generate conclusive evidence on the use of hydroxychloroquine in the prevention and treatment of COVID-19 in pregnant women.

Hydroxychloroquine is one of the drugs that has raised the greatest expectations as a possible treatment for COVID-19. It is currently used to prevent and treat malaria and in the treatment of other diseases, including rheumatoid arthritis. Two recent studies have suggested that it may be effective in reducing the viral load of SARS-CoV-2, the novel coronavirus that causes COVID-19, although the results are inconclusive and further research is needed.

The main objectives of COVID-Preg are to determine the effect of hydroxychloroquine on disease progression in pregnant women who test positive for COVID-19 and to assess its efficacy in preventing the infection in pregnant women who test negative. The clinical trial will enrol more than 700 pregnant women: half will receive hydroxychloroquine for 14 days and the other half will receive a placebo. On completion of the treatment, the women will be retested for the presence of SARS-CoV-2. Routine follow-up will continue until delivery, when the newborns will be tested to rule out maternal transmission of the infection.

 

More information:
ISGlobal website